nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

03.08.2022 | Editorial

[⁶⁴Cu]Cu-ATSM: an emerging theranostic agent for cancer and neuroinflammation

verfasst von: Fang Xie, Weijun Wei

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 12/2022

Einloggen, um Zugang zu erhalten

Excerpt

In the current issue of the European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI), Yoo et al. [1] reported that [⁶⁴Cu][Cu(ATSM-FITC)] positron emission tomography (PET) could accurately detect hydrogen sulfide (H₂S) in brain pathophysiology, opening a new horizon for detecting neuroinflammation by mapping H₂S level. In the below paragraphs, we first would like to introduce several targets and associated tracers used for detecting neuroinflammation and then the theranostic potential of [⁶⁴Cu]Cu-ATSM in preclinical and clinical settings. At the end of the manuscript, we will highlight the findings and potential applications of [⁶⁴Cu][Cu(ATSM-FITC)] reported by Yoo et al. By introducing the background and the most recent proceedings, readers may get a balanced understanding of the relevant information. …

Nam B, Lee W, Sarkar S, Kim JH, Bhise A, Park H, et al. In vivo detection of hydrogen sulfide in the brain of live mouse: application in neuroinflammation models. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-022-05854-1.

Jain P, Chaney AM, Carlson ML, Jackson IM, Rao A, James ML. Neuroinflammation PET imaging: current opinion and future directions. J Nucl Med : Off Publ Soc Nucl Med. 2020;61:1107–12. https://doi.org/10.2967/jnumed.119.229443.CrossRef

Meyer JH, Cervenka S, Kim M-J, Kreisl WC, Henter ID, Innis RB. Neuroinflammation in psychiatric disorders: PET imaging and promising new targets. Lancet Psychiat. 2020;7:1064–74. https://doi.org/10.1016/s2215-0366(20)30255-8.CrossRef

Kreisl WC, Kim M-J, Coughlin JM, Henter ID, Owen DR, Innis RB. PET imaging of neuroinflammation in neurological disorders. Lancet Neurol. 2020;19:940–50. https://doi.org/10.1016/s1474-4422(20)30346-x.CrossRefPubMedPubMedCentral

Wu C, Li F, Niu G, Chen X. PET imaging of inflammation biomarkers. Theranostics. 2013;3:448–66. https://doi.org/10.7150/thno.6592.CrossRefPubMedPubMedCentral

Zhang L, Hu K, Shao T, Hou L, Zhang S, Ye W, et al. Recent developments on PET radiotracers for TSPO and their applications in neuroimaging. Acta Pharm Sin B. 2021;11:373–93. https://doi.org/10.1016/j.apsb.2020.08.006.CrossRefPubMed

Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, et al. Imaging microglial activation in Huntington’s disease. Brain Res Bull. 2007;72:148–51. https://doi.org/10.1016/j.brainresbull.2006.10.029.CrossRefPubMed

Weissman BA, Raveh L. Peripheral benzodiazepine receptors: on mice and human brain imaging. J Neurochem. 2003;84:432–7. https://doi.org/10.1046/j.1471-4159.2003.01568.x.CrossRefPubMed

Bartels AL, Willemsen AT, Doorduin J, de Vries EF, Dierckx RA, Leenders KL. [11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson’s disease? Parkinsonism Relat Disord. 2010;16:57–9. https://doi.org/10.1016/j.parkreldis.2009.05.005.CrossRefPubMed

10.

Venneti S, Lopresti BJ, Wang G, Hamilton RL, Mathis CA, Klunk WE, et al. PK11195 labels activated microglia in Alzheimer’s disease and in vivo in a mouse model using PET. Neurobiol Aging. 2009;30:1217–26. https://doi.org/10.1016/j.neurobiolaging.2007.11.005.CrossRefPubMed

11.

Schubert J, Tonietto M, Turkheimer F, Zanotti-Fregonara P, Veronese M. Supervised clustering for TSPO PET imaging. Eur J Nucl Med Mol Imaging. 2021;49:257–68. https://doi.org/10.1007/s00259-021-05309-z.CrossRefPubMedPubMedCentral

12.

Unterrainer M, Mahler C, Vomacka L, Lindner S, Havla J, Brendel M, et al. TSPO PET with [(18)F]GE-180 sensitively detects focal neuroinflammation in patients with relapsing-remitting multiple sclerosis. Eur J Nucl Med Mol Imaging. 2018;45:1423–31. https://doi.org/10.1007/s00259-018-3974-7.CrossRefPubMed

13.

Vomacka L, Albert NL, Lindner S, Unterrainer M, Mahler C, Brendel M, et al. TSPO imaging using the novel PET ligand [(18)F]GE-180: quantification approaches in patients with multiple sclerosis. EJNMMI Res. 2017;7:89. https://doi.org/10.1186/s13550-017-0340-x.CrossRefPubMedPubMedCentral

14.

Albert NL, Unterrainer M, Fleischmann DF, Lindner S, Vettermann F, Brunegraf A, et al. TSPO PET for glioma imaging using the novel ligand (18)F-GE-180: first results in patients with glioblastoma. Eur J Nucl Med Mol Imaging. 2017;44:2230–8. https://doi.org/10.1007/s00259-017-3799-9.CrossRefPubMed

15.

Pascoal TA, Benedet AL, Ashton NJ, Kang MS, Therriault J, Chamoun M, et al. Microglial activation and tau propagate jointly across Braak stages. Nat Med. 2021;27:1592–9. https://doi.org/10.1038/s41591-021-01456-w.CrossRefPubMed

16.

Plastini MJ, Desu HL, Brambilla R. Dynamic responses of microglia in animal models of multiple sclerosis. Front Cell Neurosci. 2020;14:269. https://doi.org/10.3389/fncel.2020.00269.CrossRefPubMedPubMedCentral

17.

Sucksdorff M, Matilainen M, Tuisku J, Polvinen E, Vuorimaa A, Rokka J, et al. Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis. Brain : J Neurol. 2020;143:3318–30. https://doi.org/10.1093/brain/awaa275.CrossRef

18.

Hagens MHJ, Golla SV, Wijburg MT, Yaqub M, Heijtel D, Steenwijk MD, et al. In vivo assessment of neuroinflammation in progressive multiple sclerosis: a proof of concept study with [(18)F]DPA714 PET. J Neuroinflammation. 2018;15:314. https://doi.org/10.1186/s12974-018-1352-9.CrossRefPubMedPubMedCentral

19.

Nutma E, Fancy N, Marzin M, Tsartsalis S, Muirhead RCJ, Falk I, et al. Translocator protein is a marker of activated microglia in rodent 2 models but not human neurodegenerative diseases. 2022. https://www.researchsquare.com/article/rs-1420033/v1.

20.

Beaino W, Janssen B, Kooij G, van der Pol SMA, van Het Hof B, van Horssen J, et al. Purinergic receptors P2Y12R and P2X7R: potential targets for PET imaging of microglia phenotypes in multiple sclerosis. J Neuroinflammation. 2017;14:259. https://doi.org/10.1186/s12974-017-1034-z.CrossRefPubMedPubMedCentral

21.

Van Weehaeghe D, Koole M, Schmidt ME, Deman S, Jacobs AH, Souche E, et al. [(11)C]JNJ54173717, a novel P2X7 receptor radioligand as marker for neuroinflammation: human biodistribution, dosimetry, brain kinetic modelling and quantification of brain P2X7 receptors in patients with Parkinson’s disease and healthy volunteers. Eur J Nucl Med Mol Imaging. 2019;46:2051–64. https://doi.org/10.1007/s00259-019-04369-6.CrossRefPubMed

22.

Van Weehaeghe D, Van Schoor E, De Vocht J, Koole M, Attili B, Celen S, et al. TSPO versus P2X7 as a target for neuroinflammation: an in vitro and in vivo study. J Nucl Med: Off Publ Soc Nucl Med. 2020;61:604–7. https://doi.org/10.2967/jnumed.119.231985.CrossRef

23.

van der Wildt B, Janssen B, Pekosak A, Steen EJL, Schuit RC, Kooijman EJM, et al. Novel thienopyrimidine-based PET tracers for P2Y12 receptor imaging in the brain. ACS Chem Neurosci. 2021;12:4465–74. https://doi.org/10.1021/acschemneuro.1c00641.CrossRefPubMed

24.

Tada M, Konno T, Tada M, Tezuka T, Miura T, Mezaki N, et al. Characteristic microglial features in patients with hereditary diffuse leukoencephalopathy with spheroids. Ann Neurol. 2016;80:554–65. https://doi.org/10.1002/ana.24754.CrossRefPubMed

25.

Rademakers R, Baker M, Nicholson AM, Rutherford NJ, Finch N, Soto-Ortolaza A, et al. Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nat Genet. 2011;44:200–5. https://doi.org/10.1038/ng.1027.CrossRefPubMedPubMedCentral

26.

Zhou X, Ji B, Seki C, Nagai Y, Minamimoto T, Fujinaga M, et al. PET imaging of colony-stimulating factor 1 receptor: a head-to-head comparison of a novel radioligand, (11)C-GW2580, and (11)C-CPPC, in mouse models of acute and chronic neuroinflammation and a rhesus monkey. J Cereb Blood Flow Metab : Off J Int Soc Cereb Blood Flow Metab. 2021;41:2410–22. https://doi.org/10.1177/0271678X211004146.CrossRef

27.

Horti AG, Naik R, Foss CA, Minn I, Misheneva V, Du Y, et al. PET imaging of microglia by targeting macrophage colony-stimulating factor 1 receptor (CSF1R). Proc Natl Acad Sci USA. 2019;116:1686–91. https://doi.org/10.1073/pnas.1812155116.CrossRefPubMedPubMedCentral

28.

Liu Y, Jiang H, Qin X, Tian M, Zhang H. PET imaging of reactive astrocytes in neurological disorders. Eur J Nucl Med Mol Imaging. 2022;49:1275–87. https://doi.org/10.1007/s00259-021-05640-5.CrossRefPubMed

29.

Logan J, Fowler JS, Volkow ND, Wang G-J, MacGregor RR, Shea C. Reproducibility of repeated measures of deuterium substituted [11C]L-deprenyl ([11C]L-deprenyl-D2) binding in the human brain. Nucl Med Biol. 2000;27:43–9. https://doi.org/10.1016/s0969-8051(99)00088-8.CrossRefPubMed

30.

Villemagne VL, Harada R, Dore V, Furumoto S, Mulligan R, Kudo Y, et al. First-in-human evaluation of (18)F-SMBT-1, a novel (18)F-labeled MAO-B PET tracer for imaging reactive astrogliosis. Journal of nuclear medicine: official publication. J Nucl Med. 2022;jnumed.121.263254. https://doi.org/10.2967/jnumed.121.263254

31.

Harada R, Hayakawa Y, Ezura M, Lerdsirisuk P, Du Y, Ishikawa Y, et al. (18)F-SMBT-1: a selective and reversible PET tracer for monoamine oxidase-B imaging. J Nucl Med: Off Publ Soc Nucl Med. 2021;62:253–8. https://doi.org/10.2967/jnumed.120.244400.CrossRef

32.

Kim MJ, Lee JH, Juarez Anaya F, Hong J, Miller W, Telu S, et al. First-in-human evaluation of [(11)C]PS13, a novel PET radioligand, to quantify cyclooxygenase-1 in the brain. Eur J Nucl Med Mol Imaging. 2020;47:3143–51. https://doi.org/10.1007/s00259-020-04855-2.CrossRefPubMedPubMedCentral

33.

Shrestha S, Kim MJ, Eldridge M, Lehmann ML, Frankland M, Liow JS, et al. PET measurement of cyclooxygenase-2 using a novel radioligand: upregulation in primate neuroinflammation and first-in-human study. J Neuroinflammation. 2020;17:140. https://doi.org/10.1186/s12974-020-01804-6.CrossRefPubMedPubMedCentral

34.

Zhang X, Bian J-S. Hydrogen sulfide: a neuromodulator and neuroprotectant in the central nervous system. ACS Chem Neurosci. 2014;5:876–83. https://doi.org/10.1021/cn500185g.CrossRefPubMed

35.

Moore PK, Bhatia M, Moochhala S. Hydrogen sulfide: from the smell of the past to the mediator of the future? Trends Pharmacol Sci. 2003;24:609–11. https://doi.org/10.1016/j.tips.2003.10.007.CrossRefPubMed

36.

Paul BD, Snyder SH. Gasotransmitter hydrogen sulfide signaling in neuronal health and disease. Biochem Pharmacol. 2018;149:101–9. https://doi.org/10.1016/j.bcp.2017.11.019.CrossRefPubMed

37.

Hu L-F, Lu M, Hon Wong PT, Bian J-S. Hydrogen sulfide: neurophysiology and neuropathology. Antioxid Redox Signal. 2010;15:405–19. https://doi.org/10.1089/ars.2010.3517.CrossRef

38.

Matsumoto H, Yoshii Y, Baden A, Kaneko E, Hashimoto H, Suzuki H, et al. Preclinical pharmacokinetic and safety studies of copper-diacetyl-bis(N(4)-methylthiosemicarbazone) (Cu-ATSM): translational studies for internal radiotherapy. Transl Oncol. 2019;12:1206–12. https://doi.org/10.1016/j.tranon.2019.05.017.CrossRefPubMedPubMedCentral

39.

Vavere AL, Lewis JS. Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia. Dalton Trans. 2007;(43):4893–902. https://doi.org/10.1039/b705989b.

40.

Dearling JL, Packard AB. On the destiny of (copper) species. J Nucl Med. 2014;55:7–8. https://doi.org/10.2967/jnumed.113.132480.CrossRefPubMed

41.

Dearling JL, Packard AB. Some thoughts on the mechanism of cellular trapping of Cu(II)-ATSM. Nucl Med Biol. 2010;37:237–43. https://doi.org/10.1016/j.nucmedbio.2009.11.004.CrossRefPubMed

42.

Obata A, Yoshimi E, Waki A, Lewis JS, Oyama N, Welch MJ, et al. Retention mechanism of hypoxia selective nuclear imaging/radiotherapeutic agent cu-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) in tumor cells. Ann Nucl Med. 2001;15:499–504. https://doi.org/10.1007/BF02988502.CrossRefPubMed

43.

Holland JP, Giansiracusa JH, Bell SG, Wong LL, Dilworth JR. In vitro kinetic studies on the mechanism of oxygen-dependent cellular uptake of copper radiopharmaceuticals. Phys Med Biol. 2009;54:2103–19. https://doi.org/10.1088/0031-9155/54/7/017.CrossRefPubMed

44.

Yoshii Y, Yoneda M, Ikawa M, Furukawa T, Kiyono Y, Mori T, et al. Radiolabeled Cu-ATSM as a novel indicator of overreduced intracellular state due to mitochondrial dysfunction: studies with mitochondrial DNA-less rho0 cells and cybrids carrying MELAS mitochondrial DNA mutation. Nucl Med Biol. 2012;39:177–85. https://doi.org/10.1016/j.nucmedbio.2011.08.008.CrossRefPubMed

45.

Lewis JS, McCarthy DW, McCarthy TJ, Fujibayashi Y, Welch MJ. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med. 1999;40:177–83.PubMed

46.

Maurer RI, Blower PJ, Dilworth JR, Reynolds CA, Zheng Y, Mullen GE. Studies on the mechanism of hypoxic selectivity in copper bis(thiosemicarbazone) radiopharmaceuticals. J Med Chem. 2002;45:1420–31. https://doi.org/10.1021/jm0104217.CrossRefPubMed

47.

White C, Kambe T, Fulcher YG, Sachdev SW, Bush AI, Fritsche K, et al. Copper transport into the secretory pathway is regulated by oxygen in macrophages. J Cell Sci. 2009;122:1315–21. https://doi.org/10.1242/jcs.043216.CrossRefPubMedPubMedCentral

48.

Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med. 1997;38:1155–60.PubMed

49.

Takahashi N, Fujibayashi Y, Yonekura Y, Welch MJ, Waki A, Tsuchida T, et al. Evaluation of 62Cu labeled diacetyl-bis(N4-methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer. Ann Nucl Med. 2000;14:323–8. https://doi.org/10.1007/BF02988690.CrossRefPubMed

50.

Lewis JS, Sharp TL, Laforest R, Fujibayashi Y, Welch MJ. Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation. J Nucl Med. 2001;42:655–61.PubMed

51.

O’Donoghue JA, Zanzonico P, Pugachev A, Wen B, Smith-Jones P, Cai S, et al. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys. 2005;61:1493–502. https://doi.org/10.1016/j.ijrobp.2004.12.057.CrossRefPubMed

52.

Lohith TG, Kudo T, Demura Y, Umeda Y, Kiyono Y, Fujibayashi Y, et al. Pathophysiologic correlation between 62Cu-ATSM and 18F-FDG in lung cancer. J Nucl Med. 2009;50:1948–53. https://doi.org/10.2967/jnumed.109.069021.CrossRefPubMed

53.

Kositwattanarerk A, Oh M, Kudo T, Kiyono Y, Mori T, Kimura Y, et al. Different distribution of (62) Cu ATSM and (18)F-FDG in head and neck cancers. Clin Nucl Med. 2012;37:252–7. https://doi.org/10.1097/RLU.0b013e31823eaadb.CrossRefPubMed

54.

Ikawa M, Okazawa H, Arakawa K, Kudo T, Kimura H, Fujibayashi Y, et al. PET imaging of redox and energy states in stroke-like episodes of MELAS. Mitochondrion. 2009;9:144–8. https://doi.org/10.1016/j.mito.2009.01.011.CrossRefPubMed

55.

Ikawa M, Okazawa H, Kudo T, Kuriyama M, Fujibayashi Y, Yoneda M. Evaluation of striatal oxidative stress in patients with Parkinson’s disease using [62Cu]ATSM PET. Nucl Med Biol. 2011;38:945–51. https://doi.org/10.1016/j.nucmedbio.2011.02.016.CrossRefPubMed

56.

Isozaki M, Kiyono Y, Arai Y, Kudo T, Mori T, Maruyama R, et al. Feasibility of 62Cu-ATSM PET for evaluation of brain ischaemia and misery perfusion in patients with cerebrovascular disease. Eur J Nucl Med Mol Imaging. 2011;38:1075–82. https://doi.org/10.1007/s00259-011-1734-z.CrossRefPubMed

57.

Tateishi K, Tateishi U, Sato M, Yamanaka S, Kanno H, Murata H, et al. Application of 62Cu-diacetyl-bis (N4-methylthiosemicarbazone) PET imaging to predict highly malignant tumor grades and hypoxia-inducible factor-1alpha expression in patients with glioma. AJNR Am J Neuroradiol. 2013;34:92–9. https://doi.org/10.3174/ajnr.A3159.CrossRefPubMedPubMedCentral

58.

Dehdashti F, Mintun MA, Lewis JS, Bradley J, Govindan R, Laforest R, et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging. 2003;30:844–50. https://doi.org/10.1007/s00259-003-1130-4.CrossRefPubMed

59.

Dehdashti F, Grigsby PW, Mintun MA, Lewis JS, Siegel BA, Welch MJ. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys. 2003;55:1233–8. https://doi.org/10.1016/s0360-3016(02)04477-2.CrossRefPubMed

60.

Lewis J, Laforest R, Buettner T, Song S, Fujibayashi Y, Connett J, et al. Copper-64-diacetyl-bis(N4-methylthiosemicarbazone): an agent for radiotherapy. Proc Natl Acad Sci U S A. 2001;98:1206–11. https://doi.org/10.1073/pnas.98.3.1206.CrossRefPubMedPubMedCentral

61.

McMillan DD, Maeda J, Bell JJ, Genet MD, Phoonswadi G, Mann KA, et al. Validation of 64Cu-ATSM damaging DNA via high-LET Auger electron emission. J Radiat Res. 2015;56:784–91. https://doi.org/10.1093/jrr/rrv042.CrossRefPubMedPubMedCentral

62.

Obata A, Yoshimoto M, Kasamatsu S, Naiki H, Takamatsu S, Kashikura K, et al. Intra-tumoral distribution of (64)Cu-ATSM: a comparison study with FDG. Nucl Med Biol. 2003;30:529–34. https://doi.org/10.1016/s0969-8051(03)00047-7.CrossRefPubMed

63.

Lewis JS, Laforest R, Dehdashti F, Grigsby PW, Welch MJ, Siegel BA. An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix. J Nucl Med. 2008;49:1177–82. https://doi.org/10.2967/jnumed.108.051326.CrossRefPubMed

64.

Savi A, Incerti E, Fallanca F, Bettinardi V, Rossetti F, Monterisi C, et al. First evaluation of PET-based human biodistribution and dosimetry of (18)F-FAZA, a tracer for imaging tumor hypoxia. J Nucl Med. 2017;58:1224–9. https://doi.org/10.2967/jnumed.113.122671.CrossRefPubMed

65.

Nakajo M, Jinguji M, Tani A, Kajiya Y, Nandate T, Kitazano I, et al. [(18)F]-FDG-PET/CT and [(18)F]-FAZA-PET/CT hypoxia imaging of metastatic thyroid cancer: association with short-term progression after radioiodine therapy. Mol Imaging Biol. 2020;22:1609–20. https://doi.org/10.1007/s11307-020-01516-6.CrossRefPubMed

66.

Little PV, Arnberg F, Jussing E, Lu L, Ingemann Jensen A, Mitsios N, et al. The cellular basis of increased PET hypoxia tracer uptake in focal cerebral ischemia with comparison between [(18)F]FMISO and [(64)Cu]CuATSM. J Cereb Blood Flow Metab. 2021;41:617–29. https://doi.org/10.1177/0271678X20923857.CrossRefPubMed

67.

Williamson DJ, Ejaz S, Sitnikov S, Fryer TD, Sawiak SJ, Burke P, et al. A comparison of four PET tracers for brain hypoxia mapping in a rodent model of stroke. Nucl Med Biol. 2013;40:338–44. https://doi.org/10.1016/j.nucmedbio.2012.11.012.CrossRefPubMed

68.

Takasawa M, Moustafa RR, Baron JC. Applications of nitroimidazole in vivo hypoxia imaging in ischemic stroke. Stroke. 2008;39:1629–37. https://doi.org/10.1161/STROKEAHA.107.485938.CrossRefPubMed

69.

Liu T, Redalen KR, Karlsen M. Development of an automated production process of [(64) Cu][Cu (ATSM)] for positron emission tomography imaging and theranostic applications. J Labelled Comp Radiopharm. 2022;65:191–202. https://doi.org/10.1002/jlcr.3973.CrossRefPubMedPubMedCentral

70.

Laforest R, Dehdashti F, Lewis JS, Schwarz SW. Dosimetry of 60/61/62/64Cu-ATSM: a hypoxia imaging agent for PET. Eur J Nucl Med Mol Imaging. 2005;32:764–70. https://doi.org/10.1007/s00259-004-1756-x.CrossRefPubMed

71.

Yoshii Y, Matsumoto H, Yoshimoto M, Zhang MR, Oe Y, Kurihara H, et al. Multiple administrations of (64)Cu-ATSM as a novel therapeutic option for glioblastoma: a translational study using mice with xenografts. Transl Oncol. 2018;11:24–30. https://doi.org/10.1016/j.tranon.2017.10.006.CrossRefPubMed

72.

Yoshii Y, Matsumoto H, Yoshimoto M, Furukawa T, Morokoshi Y, Sogawa C, et al. Controlled administration of penicillamine reduces radiation exposure in critical organs during 64Cu-ATSM internal radiotherapy: a novel strategy for liver protection. PLoS ONE. 2014;9:e86996. https://doi.org/10.1371/journal.pone.0086996.CrossRefPubMedPubMedCentral

73.

Igarashi C, Matsumoto H, Takahashi M, Hihara F, Tachibana T, Zhang MR, et al. Identification and quantitative structure-activity relationship assessment of trace chemical impurities contained in the therapeutic formulation of [(64)Cu]Cu-ATSM. Nucl Med Biol. 2022;108–109:10–5. https://doi.org/10.1016/j.nucmedbio.2022.02.001.CrossRefPubMed

74.

Liu T, Karlsen M, Karlberg AM, Redalen KR. Hypoxia imaging and theranostic potential of [(64)Cu][Cu(ATSM)] and ionic Cu(II) salts: a review of current evidence and discussion of the retention mechanisms. EJNMMI Res. 2020;10:33. https://doi.org/10.1186/s13550-020-00621-5.CrossRefPubMedPubMedCentral

75.

Yoshii Y, Furukawa T, Kiyono Y, Watanabe R, Waki A, Mori T, et al. Copper-64-diacetyl-bis (N4-methylthiosemicarbazone) accumulates in rich regions of CD133+ highly tumorigenic cells in mouse colon carcinoma. Nucl Med Biol. 2010;37:395–404. https://doi.org/10.1016/j.nucmedbio.2009.12.011.CrossRefPubMed

76.

Yoshii Y, Furukawa T, Kiyono Y, Watanabe R, Mori T, Yoshii H, et al. Internal radiotherapy with copper-64-diacetyl-bis (N4-methylthiosemicarbazone) reduces CD133+ highly tumorigenic cells and metastatic ability of mouse colon carcinoma. Nucl Med Biol. 2011;38:151–7. https://doi.org/10.1016/j.nucmedbio.2010.08.009.CrossRefPubMed

77.

Wallace JL, Wang R. Hydrogen sulfide-based therapeutics: exploiting a unique but ubiquitous gasotransmitter. Nat Rev Drug Discov. 2015;14:329–45. https://doi.org/10.1038/nrd4433.CrossRefPubMed

78.

Pyun J, McInnes LE, Donnelly PS, Mawal C, Bush AI, Short JL, et al. Copper bis(thiosemicarbazone) complexes modulate P-glycoprotein expression and function in human brain microvascular endothelial cells. J Neurochem. 2022;(3):226-244. https://doi.org/10.1111/jnc.15609

79.

Sarkar S, Ha YS, Soni N, An GI, Lee W, Kim MH, et al. Immobilization of the gas signaling molecule H2 S by radioisotopes: detection, quantification, and in vivo imaging. Angew Chem Int Ed Engl. 2016;55:9365–70. https://doi.org/10.1002/anie.201603813.CrossRefPubMed

80.

Cheng XT, Huang N, Sheng ZH. Programming axonal mitochondrial maintenance and bioenergetics in neurodegeneration and regeneration. Neuron. 2022;110(12):1899–1923.

81.

Eldeeb MA, Thomas RA, Ragheb MA, Fallahi A, Fon EA. Mitochondrial quality control in health and in Parkinson's disease. Physiol Rev. 2022;102(4):1721–1755.

82.

Cisneros J, Belton TB, Shum GC, Molakal CG, Wong YC. Mitochondria-lysosome contact site dynamics and misregulation in neurodegenerative diseases. Trends Neurosci. 2022;45:312–22. https://doi.org/10.1016/j.tins.2022.01.005.CrossRefPubMed

83.

Amorim JA, Coppotelli G, Rolo AP, Palmeira CM, Ross JM, Sinclair DA. Mitochondrial and metabolic dysfunction in ageing and age-related diseases. Nat Rev Endocrinol. 2022;18:243–58. https://doi.org/10.1038/s41574-021-00626-7.CrossRefPubMedPubMedCentral

84.

Lewis JS, Herrero P, Sharp TL, Engelbach JA, Fujibayashi Y, Laforest R, et al. Delineation of hypoxia in canine myocardium using PET and copper(II)-diacetyl-bis(N(4)-methylthiosemicarbazone). J Nucl Med. 2002;43:1557–69.PubMed

85.

Nie X, Elvington A, Laforest R, Zheng J, Voller TF, Zayed MA, et al. (64)Cu-ATSM positron emission tomography/magnetic resonance imaging of hypoxia in human atherosclerosis. Circ Cardiovasc Imaging. 2020;13:e009791. https://doi.org/10.1161/CIRCIMAGING.119.009791.CrossRefPubMedPubMedCentral

Titel: [64Cu]Cu-ATSM: an emerging theranostic agent for cancer and neuroinflammation
verfasst von: Fang Xie
Weijun Wei
Publikationsdatum: 03.08.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 12/2022
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-022-05887-6

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2022

In vivo detection of hydrogen sulfide in the brain of live mouse: application in neuroinflammation models

Direct inference of Patlak parametric images in whole-body PET/CT imaging using convolutional neural networks

Primary biphasic synovial sarcoma of the liver with multiple bone metastases detected by PET/CT

Complementary value of metabolic and tau PET imaging in the diagnosis of corticobasal degeneration

The role of 18F-FDG PET/CT in predicting the pathological response to neoadjuvant PD-1 blockade in combination with chemotherapy for resectable esophageal squamous cell carcinoma

Preclinical evaluation and pilot clinical study of [18F]AlF-NOTA-FAPI-04 for PET imaging of rheumatoid arthritis